KEFLEX

Compare KEFLEX  to:
Compare
Compare

Generic Name for KEFLEX

Cephalexin 250mg, 333mg, 500mg, 750mg; caps.

Legal Classification:

Rx

Pharmacological Class for KEFLEX

Cephalosporin.

Manufacturer of KEFLEX

MiddleBrook Pharmaceuticals

Indications for KEFLEX

Susceptible infections including otitis media, skin and skin structure, bone, respiratory or genitourinary tract.

Adult dose for KEFLEX

1–4g/day in divided doses. Usual dose: 250mg every 6 hours. Strep pharyngitis, skin and skin structure, and uncomplicated cystitis (>15 years of age): 500mg every 12 hours. Treat cystitis for 7–14 days. Max 4g/day.

Children's dosing for KEFLEX

25–50mg/kg per day in divided doses; max 100mg/kg per day. Otitis media: 75–100mg/kg per day in 4 divided doses. Strep pharyngitis (>1 year of age) or skin and skin structure: may give in 2 divided doses every 12 hours.

Precautions for KEFLEX

Penicillin or other allergy. Severe renal dysfunction. GI disease (esp. colitis). Discontinue if colitis occurs and treat. Pregnancy (Cat.B). Nursing mothers.

Interactions for KEFLEX

Potentiates metformin (monitor and adjust metformin dose). Potentiated by probenecid. May cause false (+) Coomb's test or glucose test with Clinitest or Benedict's or Fehling's soln.

Adverse Reactions for KEFLEX

Diarrhea, other GI disturbances, dizziness, fatigue, headache, hypersensitivity reactions, itch; rare: blood dyscrasias, elevated liver enzymes.

How is KEFLEX supplied?

Caps 250mg, 500mg—20, 100
333mg—(available soon)
750mg—50

Related Disease:

Infections, bacterial~systemic antiinfectives

Related Resources

Cayston inhaled antibiotic approved for cystic fibrosis

February 23, 2010

The FDA has approved Cayston (aztreonam for inhalation solution, from Gilead Sciences) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

Phase 3 study of fidaxomicin for clostridium difficile infection (CDI)

February 05, 2010

Optimer Pharmaceuticals announced positive top-line results from the second of two Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI).

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of Arikace for treatment of pseudomonas lung infections

October 19, 2009

Transave reported additional positive clinical trial results on its lead investigational drug, Arikace (liposomal amikacin for inhalation), an antibiotic to treat chronic lung infections.

Vibativ approved for complicated skin and skin structure infections

September 18, 2009

The FDA has approved Vibativ (telavancin, from Theravance and Astellas), a bactericidal, once-daily injectable lipoglycopeptide antibiotic.